Pharmacokinetic monitoring is still required for intravenous busulfan in SCT for small children

International Journal of Hematology

Volumn 91, Issue 4, 2010, Pages 728-730

  Nagasawa, Masayuki ^a   Mitsuiki, Noriko ^a   Ono, Toshiaki ^a   Takagi, Masatoshi ^a   Oda, Hiromi ^a   Yasuhara, Masato ^a   Mizutani, Shuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMATINIB; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; BLOOD SAMPLING; CHILD; DRUG MONITORING; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; HYPER IGM SYNDROME; IMMUNE DEFICIENCY; LETTER; MONITORING; SEVERE COMBINED IMMUNODEFICIENCY; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION; WISKOTT ALDRICH SYNDROME;

BUSULFAN; CHILD; DRUG MONITORING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 77954486809     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0572-2     Document Type: Letter

References (8)

1. Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV, Norstad D, Cowan MJ. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2001;28:1013-1018
2. Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, Galambrun C, Dai Q, Maire P, Jelliffe RW, Aulagner G. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28:743-751
3. Vassal G, Michel G, Esperou H, Gentet JC, Valteau-Couanet D, Doz F, Mechinaud F, Galambrun C, Neven B, Zouabi H, Nguyen L, Puozzo C. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without monitoring. Cancer Chemother Pharmacol. 2008;61:113-123
4. Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G, Dupuis LL. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:307-314
5. Nishikawa T, Okamoto Y, Tanabe T, Shinkoda Y, Kodama Y, Higashi M, Hirano H, Arita K, Kawano Y. Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation. Bone Marrow Transplant. 2009;45:602-604
6. Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, Yagasaki F, Kawai Y, Miyawaki S, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood. 2004;104:3507-3512
7. Vaughan WP, Cagnoni P, Fernandez H, Hu W, Kashyap A, Gian V, Wingard J, Tarantolo S, Andersson BS. Decreased incidence of and risk factors for hepatic veno-occlusive disease with an intravenous busulfan (BU) containing preparative regimen for hematopoietic stem cell transplantation (HSCT). Blood. 1998;92(Suppl. 1):516a.
8. Johnson L, Orchard PJ, Baker KS, Brundage R, Cao Q, Wang X, Langer E, Farag-El Maasah S, Ross JA, Remmel R, Jacobson PA. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J Clin Pharmacol. 2008;48(9):1052-1062